Comparative Pharmacology
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 370.
HEXABRIX vs ISOVUE-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
Intravenous injection of 50-200 mL of Isovue-370 (iopamidol 76% solution, 370 mg I/mL) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 mL total volume.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 mL/min); prolonged to up to 30 hours in severe renal impairment.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Media
Contrast Media